Aakash Gupta says the NYT profile of Medvi as an AI mega-success omits an FDA warning letter for misbranding, implying hype can outrun compliance reality.
The NYT just profiled Medvi as the AI success story of the decade.
$1.8B in projected revenue, 2 employees
Medvi received FDA Warning Letter #721455 in February 2026 for misbranding violations.
This finding is one of many signals tracked across Indiehacking. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Indiehacking